Checkpoint inhibitor 单药-天津市肿瘤医院张新伟教授.pdf

2017ASCO肺癌进展

Checkpointinhibitor单药

天津市肿瘤医院张新伟

ApprovedPD-1/PD-L1inhibitors

GenericnameNivolumabPembrolizumabAtezolizumabAvelumabDurvalumab

BMSMerckRocheMerck/PfizerAstraZeneca

Melanoma2014-12-222014-9-4

2015-10-12015-12-18

2016-1-23

NSCLC2015-3-42015-10-22016-10-18

2015-10-92016-10-24

2017-5-10

RCC2015-11-23

ClassicalHD2016-5-172016-3-15

squamousHN2016-10-112016-8-5

Urothelial2017-2-22017-5-182016-5-182017-3-232017-5-1

carcinoma2017-4-17

MerkelCell2017-5-9

Carcinoma

SolidTumor217-5-23

withMSI-H

AdverseEvents(AEs)

PresentedByMelissaJohnsonat2017ASCOAnnualMeeting

ImmuneRelatedAdverseEvents(IRAEs)

PresentedByMelissaJohnsonat2017ASCOAnnualMeeting

PD1vs.PDL1—ifitcomesdowntoCostandconvenience

PresentedByMelissaJohnsonat2017ASCOAnnualMeeting

PD1/PD-L1—Allthesame?Isonethebest?

PresentedByMelissaJohnsonat2017ASCOAnnualMeeting

JClinOncol35,2017(suppl;abstr8508)

JClinOncol35,2017(suppl;abstr9000)

二线治疗的无进展生存：PFS2

1

•正如EMA2012年首次定义的那样：在后线治疗时，从随机分组至客

观肿瘤进展或因任何原因死亡的时间，以先出现者为准

死亡

治疗方案1治疗方案2不治疗

PFS

PFS2

OS

用于评价交叉治疗对OS的影响